ABSTRACT
NABI has an HIV HYPERIVIG product in development. This product, HIV-IG, was manufactured according to the above described methodology. This preparation is currently undergoing evaluation in Phase III clinical trials for the prevention of HIV vertical transmission in HIV + pregnant women (137). Other planned studies include evaluation for the prevention of infection in infants at a single non-U.S. site by treating just the neonate for prevention of HIV vertical transmission. An additional study evaluated the HIV HYPERIVIG for treatment of HIV + children (137).
